Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA) has been given a consensus rating of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $16.00.

Several research analysts have recently weighed in on COYA shares. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a report on Monday, March 16th. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday. Chardan Capital restated a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research note on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC raised its position in shares of Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after buying an additional 13,176 shares in the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Coya Therapeutics in the second quarter worth $119,000. JPMorgan Chase & Co. purchased a new position in Coya Therapeutics in the third quarter worth $28,000. CM Management LLC increased its stake in Coya Therapeutics by 50.0% in the third quarter. CM Management LLC now owns 300,000 shares of the company’s stock valued at $1,710,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Dauntless Investment Group LLC raised its position in Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares in the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Trading Up 0.2%

Shares of NASDAQ:COYA opened at $4.22 on Tuesday. The company has a 50 day moving average of $4.68 and a 200 day moving average of $5.50. The stock has a market cap of $99.00 million, a P/E ratio of -3.32 and a beta of 0.23. Coya Therapeutics has a 12 month low of $3.94 and a 12 month high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Monday, March 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.26). Coya Therapeutics had a negative return on equity of 62.76% and a negative net margin of 267.13%.The firm had revenue of $3.96 million during the quarter, compared to analysts’ expectations of $1.93 million. On average, equities analysts forecast that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical?stage biotechnology company focused on the discovery and development of first?in?class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small?molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.